Educating Through Medical Animations, Cases and More | Free CME Activities

Education

Search

Beyond Pulmonary

Browse over 450 CME/CE courses on FranceFoundation.com

VIEW ALL EDUCATION

Page 8 of 8

Results 526 - 580 of 580

What Do the Experts Say about New Developments in the Diagnosis of ILD?

Is the delivery system a good match for your patients with COPD?

Stepping up or stepping down – which direction for COPD patients?

What’s the 2017 GOLD standard for managing patients with COPD?

UIP, IPF, NSIP, CHP: Making Sense of the Letters

t2diabetes-louise

Getting to Goal Can Be Difficult: Louise

t2diabetes-brian

Getting to Goal Can Be Difficult: Brian

Considering Biosimilars in Patients Failing their Initial Biologic

When to Switch? Biologically Experienced Patients with Spondyloarthritis

Innovator or Biosimilar for a Patient with Rheumatoid Arthritis

IL-gastro-case3

Ulcerative Colitis: What Can You Expect When a Patient is Switched to a Biosimilar?

IL-gastro-case2

Biosimilars in Patients with Crohn’s Disease Failing an Initial Biologic

IL-gastro-case1

Innovator or Biosimilar for a Patient with Ulcerative Colitis?

Switching Between Biologics: Is a Biosimilar an Option?

When to Switch? Biologically Experienced Psoriasis Patients

Innovator or Biosimilar for a Patient with Psoriasis

Interchangeability and Pharmacy-Level Substitution

FDA Criteria: Biosimilar Approval, Manufacturing, & Naming

What is the Difference Between a Biosimilar and a Generic?

What is a Biologic?

New Strides in EGFR Inhibition for Non–Small Cell Lung Cancer

Pete - Work-Up of a Patient with Right Upper Lobe Mass and Metastases

Carl - High Suspicion of Lung Cancer: Setting the Stage with a Good Biopsy

Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics

Are You Ready to Use Biosimilars in Your Practice?

Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?

Pharmacovigilance and Biosimilars: Any Special Considerations?

Interchangeability and Biosimilars: What will this Mean for Clinical Practice?

Can a Biosimilar be Used for the Same Indications Approved for the Reference Biologic?

Biosimilars: As Safe and Effective as the Reference Product?

Drift and the Manufacturing of Biologics: What is it and Does it Matter?

Radiologic Features of IPF

Gwen: A lawyer with a history of MI has a dry cough and trouble with stairs

Elizabeth: Loves the outdoors but bothered by persistent cough and GERD

Toni: Too tired to continue teaching and experiencing painful heartburn

Individualizing Patient Education in Treatment Choice: Practical Strategies

A 30 y/o Female w/2-year History of Shoulder Weakness and Elevated AST and ALT

32 y/o Male w/Progressive Weakness, Dilated Cardiomyopathy & Respiratory...

A 60 y/o Male w/4-year History Of Shoulder Weakness

Biosimilars in Clinical Practice: Interchangeability and Extrapolation

Individualizing Patient Education in Treatment Choice: Practical Strategies

Addressing Common Barriers to Adherence

Approach to Genetic Testing in Myopathies

Molecular Diagnosis of Limb-Girdle Muscle Weakness

Discovering New Drugs for IPF

Biomarkers for IPF

New Trends in IPF

New Trends in IPF

Treatment Dilemmas Case Study: Harrison

A New Era in IPF: Trials and Treatments

Highlights from ATS 2014: Discussions on Clinical Trial Data

Highlights from ATS 2014: Update on Predicting Clinical Progression

Highlights from ATS 2014: Top Line Clinical Trial Results - ASCEND, INPULSIS, and PANTHER

Exciting IPF Developments from 2015 ERS

Exciting Developments from 2015 CHEST

Page 8 of 8